Back
NF1HGNC PubMedNew recommendation

Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium

Romo CG, Ahlawat S, Amrami KK, et al. — Neuro Oncol 2026 · November 2026
Relevance score
5/10
Disease / domain
Neurofibromatosis type 1 — peripheral nerve sheath tumours at risk of malignant transformation
Source
PubMed
PMID 43021633

Gene / mechanism

NF1

Germline NF1 variants; transformation of benign peripheral nerve sheath tumours into malignant tumours (MPNST)

Summary

People with neurofibromatosis type 1 (NF1) develop peripheral nerve sheath tumours (PNSTs) ranging from benign neurofibromas to high-grade sarcomas, and atypical neurofibromas are at increased risk of malignant transformation. The term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential), proposed in 2017 on histopathological criteria, does not cover PNSTs with concerning clinical, imaging or molecular features that do not meet those criteria. A State of the Science conference reached consensus on how to define these pre-cancerous lesions, on their clinical management and on research priorities. It recommends defining pre-malignant at-risk PNSTs by a combination of histological, molecular and imaging features, and dividing people with NF1 into higher-risk and average-risk groups for MPNST based on the germline NF1 variant, internal tumour burden and history of malignancy or radiotherapy. Finally, it stresses the need to validate screening and surveillance strategies based on these personal and tumour-related risk factors.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

Stratifying people with NF1 into higher or average MPNST risk, with the germline variant as one input, gives the genetic result an explicit role in organising follow-up. The consensus nevertheless remains qualitative: the abstract gives neither thresholds nor surveillance intervals, and the consensus method is not described. It is a shared working framework for expert centres rather than an operational care pathway.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 1/3Novelty 2/2Sample 0/1Publication 0/1

Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 2/2 · Sample size: 0/1 · Publication status: 0/1 → Total: 5/10

Keywords

neurofibromatosis type 1NF1atypical neurofibromaMPNSTconsensus

More articles on NF1

Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime